1. Nishiuchi K, Ohashi H, Nishioka K, Yamasaki M, Furuta M, Mashiko T, Tomoshige S, Ohgane K, Kamisuki S, Watashi K, Kuramochi K. Synthesis and Antiviral Activities of Neoechinulin B and Its Derivatives. J Nat Prod 85(1): 284-291 (2022)
2. Shionoya K, Yamasaki M, Iwanami S, Ito Y, Fukushi S, Ohashi H, Saso W, Tanaka T, Aoki S, Kuramochi K, Iwami S, Takahashi Y, Suzuki T, Muramatsu M, Takeda M, Wakita T, Watashi K. Mefloquine, a Potent anti-Severe Acute Respiratory Syndrome-related Coronavirus 2 (SARS-CoV-2) drug as an entry inhibitor in vitro. Front Microbiol. 2021, in press.
3. Tsuji G, Nakajima S, Watashi K, Torii S, Suzuki R, Fukuhara T, Ohoka N, Inoue T, Demizu Y. Antiviral activity of ciclesonide acetatal derivatives blocking SARS-CoV-2 RNA replication. J Pharmacol Sci (in press)
4. Wing PAC, Keeley TP, Zhuang X, Lee JY, Prange-Barczynska M, Tsukuda S, Morgan SB, Argles ILA, Kurlekar S, Noerenberg M, Thompson CP, Huang KYA, Balfe P, Watashi K, Castello A, Hinks TSC, James W, Ratcliffe PJ, Davis I, Hodson EJ, Bishop T, McKeating JA. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. Cell Rep. 2021, in press
5. Hijikata A, Shionyu-Mitsuyama C, Nakae S, Shionyu M, Ota M, Kanaya S, Hirokawa T, Nakajima S, Watashi K, Shirai T. Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2. FEBS Open Bio 12(1): 285-294 (2022)
6. Kim KS, Ejima K, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Asai Y, Nakaoka S, Watashi K, Aihara K, Thompson RN, Ke R, Perelson AS, Iwami S. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol. 2021, 19(3): e3001128. doi: 10.1371/journal.pbio.3001128.
7. Watashi K. Open collaborative framework providing severe acute respiratory syndrome coronavirus 2 infection cell culture assays for accelerating drug development. Translat Regulat Sci 3(3): 112-114 (2021)
8. Ohashi H, Wang F, Stappenbeck F, Tsuchimoto K, Kobayashi C, Saso W, Kataoka M, Yamasaki M, Kuramochi K, Muramatsu M, Suzuki T, Sureau C, Takeda M, Wakita T, Parhami F, Watashi K. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro. Int J Mol Sci. 2021, 22(6): 3163. doi: 10.3390/ijms22063163.
9. Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T. Potential anti-COVID-19 agents, Cepharanthine and Nelfinavir, and their usage for combination treatment. iScience. 2021, 1: 102367. doi: 10.1016/j.isci.2021.102367.
10. Ejima K, Kim KS, Ludema C, Bento AI, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Watashi K, Aihara K, Nishiura H, Iwami S. Estimation of the incubation period of COVID-19 using viral load data. Epidemics. 2021, 35: 100454. doi: 10.1016/j.epidem.2021.100454.